Richmond Pharmacology is pleased to confirm our attendance at JSCPT 2025, the Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, taking place in Tokyo from 5–6 December.
Representing Richmond at JSCPT 2025:
Dr Jörg Täubel, Chief Executive Officer
Dr Ulrike Lorch, Chief Medical Director
Dr Lisa Campbell, Director of Regulatory Strategy
Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
Minoru Takada, Japanese Business Development Executive
Jennifer Martin, External Consultant
We look forward to connecting with clinical and regulatory professionals to discuss Richmond’s expertise in:
Early-phase and first-in-human studies
Bridging studies between Europe and Asia
Gene and RNA-based therapy development
Pharmacokinetics, biomarkers, and trial design
Cross-border collaboration in complex trials
If you’re attending JSCPT 2025 and seeking a clinical development partner, arrange a meeting with one of
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
